Kornimate/medical-research-clean huggingface dataset:
promotion of well-being of young adult brain cancer survivors

Conditions: Brain Tumor, Pediatric

Summary: the purpose of this study is to evaluate the effectiveness of an internet-based, behavioral activation intervention to promote well-being in a young adult survivors of childhood brain tumor.

participants will be recruited through the children's brain tumor foundation who will share the study announcement with their young adult members and social media. eligible participants will complete a baseline battery survey via qualtrics. the investigators will recruit 120 participants. the survey will take approximately 30 minutes to complete. participants will be randomly assigned to an experimental group or control group. the experimental group will take an internet-based behavioral activation intervention. the intervention has four modules and will be administered via qualtrics. a link to each module will be sent to the participants via e-mail. participants will have one week to complete each module. once a participant completes a module, the next module link will be sent after 3 days. a reminder will be sent at 7 days and 10 days until the module is complete. each module will take approximately 30 minutes to complete. the experimental group may continue to receive services as usual from the children's brain tumor foundation. the control group will continue to receive services as usual from the children's brain tumor foundation. the control group will have an opportunity to take the intervention once data collection is complete. both groups will be asked to complete a battery of surveys at the end of the intervention and intermittently over a 3-month period.

Eligibility criteria:
inclusion criteria: * history of childhood brain tumor * ages of 18 and 30 years. * have regular access to the internet * provide an e-mail address exclusion criteria: * those that do not meet the inclusion criteria.
neuropathic pain in head and neck cancer

Conditions: Head and Neck Cancer

Summary: the goal of this research study is to learn more about chronic pain associated with cancer treatment.

if you agree to take part in this study, you will complete the following tests and procedures at the beginning and at the end of the study (on clinic visits, typically around 3-6 months after completion of treatment): °you will complete 5 questionnaires about any pain and other symptoms you may have had, your general well-being, drugs you may be taking, and personal information, such as your age. the questionnaires will take about 25-50 minutes to complete. every week during treatment period, you will complete a questionnaire about pain you may be having. this questionnaire will take about 5-10 minutes to complete. length of study: you will be on study for about 3-6 months after the last day of treatment. this is an investigational study. up to 1200 will take part at md anderson.

Eligibility criteria:
inclusion criteria: 1. aim 1 discovery phase: the samples are from a large nih-funded genome-wide association study of squamous cell carcinoma of the head and neck (shete; pi). a total of 2900 "case" patients and 1200 control patients were recruited for the study. in this study, we will only use cases who were: a) newly diagnosed, untreated, histopathologically confirmed squamous cell carcinoma of the oral cavity, pharynx, or larynx; b) no previous cancers; c) age 18 years or older; d) white caucasian. 2. aim 2: a) newly diagnosed patients (have not had any prior cancer treatment) with loco-regional squamous cell carcinoma of the head and neck, b) will receive cancer treatment at mdacc or at ben taub, c) are 18 years or older, d) english or spanish speaking; e) able to understand the description of the study and give written informed consent; f) will state that they will receive follow-up at md anderson post-treatment or at ben taub. this sample will also be included in the validation phase of aim 1. we note that population stratification, i.e., the presence of a systematic difference in allele frequencies between subpopulations in a population possibly due to different ancestry, is an issue for genetic association studies. 3. aim 3: patients included in aims 1 and 2. exclusion criteria: 1) exclusion for aim 2: a) patients with distant metastasis (stage ivc); b. patients participating in clinical trials/ investigational drugs for pain control. aim 1 (discovery phase) and aim 3 will use existing data.

Keywords: neuropathic pain squamous cell cancer of the head and neck acute pain pain management genome-wide analyses squamous cell carcinoma of the head and neck chronic pain neuropathic locoregional squamous cell carcinoma of the head and neck
an online evaluation of work chat

Conditions: Autism Spectrum Disorder

Summary: this study is aiming to see if it is feasible for the intervention work chat to be delivered in a completely online setting to adults with autism spectrum disorder.

nearly 50,000 youth with autism spectrum disorder (asd) transition from high school to adult life each year, with only 25% of these transition-age youth with asd (tay-asd) getting jobs within 2 years of graduation. tay-asd's ability to sustain employment is even more challenging due in part to their social cognitive deficits (e.g., poorly reading social cues) that disrupt communicating with customers, coworkers, and supervisors. research shows nearly 90% of job dismissals among tay-asd are attributed to poor work-based social functioning (e.g., poorly communicating with upset customers). the subsequent unemployment has damaging effects on their mental, physical, and economic health. a critical gap in federally-mandated services to support youth with asd as they transition from school-to-adult life is the lack of evidence-based practice to enhance their work-based social functioning. given that tay-asd report computerized training tools are highly acceptable and improve their real-world outcomes, the investigators propose to address this critical barrier to sustained employment by developing and evaluating a novel and scalable computerized training tool to enhance their conversations with customers, coworkers and supervisors at work. the investigators are aiming to see if it is feasible for work chat to be delivered in a completely online setting and not within schools or other sites. the investigators are also evaluating the tool specifically with employed adults who have autism spectrum disorder.

Eligibility criteria:
inclusion criteria: * autism spectrum disorder * 18 years or older * has 4th grade or higher reading level * employed or unemployed and searching for employment within the next 3 months * has access to a computer, laptop, or tablet that has connection to the internet and a camera (not including smartphone) exclusion criteria: -
brain markers of suicide risk and psychological pain in elderly depressed patients

Conditions: Depressive Disorder; Suicide, Attempted

Summary: the main objective of this study is to show mri functional and structural differences between depressed elderly patients with a history of attempted suicide compared to depressed elderly patients with no history of attempted suicide and to elderly subjects with no personal history of depression or attempted suicide (healthy controls).


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * be a member or beneficiary of a health insurance plan * aged 60 years-old or more * must be right-handed * with a diagnosis of a current major depressive episode of moderate to severe severity according to diagnostic criteria. * with or without a personal history of attempted suicide during life * hospitalized or followed by a consultant in the department of psychiatry of nîmes university hospital or in the sophoras private clinic exclusion criteria: * the subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * under safeguard of justice * refuses to sign the consent * it is impossible to give the subject informed information * current psychotic symptoms. * bipolar disorder. * the subject presents an acute somatic decompensation incompatible with the realization of this study. * the patient presents a mental confusion or a known mini mental state examination score \<24. * central neurological disease known in particular degenerative pathology, severe cranial trauma and severe cerebrovascular disease. * schizophrenia and other known psychotic disorders. * electroconvulsive therapy in the 12 months prior to study * inability to perform neuropsychological tests because of a language problem, poor understanding, a major tremor, inability to sit still, a major sight problem that cannot be corrected, or other severe cognitive impairment * contra-indication to magnetic resonance imaging (mri): ferromagnetic implant in the body, piercing, claustrophobia, inability to remain elongated for 45 minutes.

Keywords: elderly mri
extension study investigating the long-term safety of degarelix one-month depots in patients with prostate cancer

Conditions: Prostate Cancer

Summary: this was an extension study for the study fe200486 cs14 (nct00116779). each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained. the study was terminated when all ongoing participants had been treated for at least 5 years.

participants who completed the main fe200486 cs14 study initially continued with the same dose in the fe200486 cs14a extension study. a protocol amendment changed the dosage to 160 mg (40 mg/ml) for all study participants. the data include data from the participants who participated in both the main study (fe200486 cs14; nct00116779) and the extension study fe200486 cs14a.

Eligibility criteria:
inclusion criteria: * has given written consent prior to any study-related activity being performed. a study-related activity is defined as any procedure that would not have been performed during the normal management of the patient. * has completed study fe200486 cs14 through visit 22. exclusion criterion: * has been withdrawn from the fe200486 cs14 study.

Keywords: prostate cancer androgen ablation therapy
effect of ultra-low dose naloxone during supraclavicular brachial plexus block on post-operative opioi

Conditions: Upper Extremity Trauma

Summary: effective post-operative pain control can reduce patient morbidity and affect the patient outcome. brachial plexus block is one of them, a popular and widely employed regional nerve block technique for perioperative anesthesia and analgesia for surgery of the upper extremity. different drugs have been used as adjuvants with local anesthetics in brachial plexus block to achieve quick, dense and prolonged block like morphine, pethidine, clonidine, dexmedetomidine. naloxone is opioid antagonists which could selectively block the excitatory effects of opioids. it release endorphins and also displace endorphins from receptor site .it also reduce the opioid induced side effects, such as vomiting, nausea, pruritus, and respiratory depression.

the aim of this study is to evaluate the effect of ultra-low dose of naloxone when added to bupivacaine %.05 in supraclavicular brachial plexus block in orthopedic upper limb surgery and if it enhances the anti-nociceptive effect of post-operative opioid effect of naloxone on anti-nociceptive criteria of post -operative opioid will be estimated by detecting the interval between each analgesic dose of post-operative opioid.

Eligibility criteria:
inclusion criteria: * american society of anesthesiology (asa) physical state class ι and ii * elective upper limb orthopedic surgery (hand, forearm and elbow) * duration of surgery ≤180 min * bmi ≤30 kg/m2 exclusion criteria: * history of allergy to the drug of the study. * coagulation disorders * infection at the puncture site. * pregnancy * opioid abuse. * abuse of tranquilizers
improving treatment of inflammatory bowel diseases through better understanding infliximab drug and antibody levels

Conditions: Crohn's Disease; Ulcerative Colitis

Summary: the purpose of this study is to develop a predictive model that will allow optimized dosing of infliximab for individual patients

the use of pharmacokinetic analyses incorporating relevant determinants of the infliximab serum concentration can be used to develop a predictive model that will allow optimized dosing for individual patients.

Eligibility criteria:
inclusion criteria: * a diagnosis of cd or uc by usual criteria, * moderate to severely active cd defined by a cdai ≥ 220, with confirmed endoscopic activity (cdeis ≥ 6) or moderate to severely active uc, defined by a mayo score ≥ 6, with a mayo endoscopic subscore ≥ 2, * a need for treatment with ifx for induction of remission as clinically indicated * patients previously exposed to adalimumab and/or certolizumab who are naïve to infliximab will be allowed to participate. exclusion criteria: * perianal cd exclusively * disease limited to the rectum in patients with uc (i.e., disease must extend ≥ 15 cm from the anal verge) * patients with known antibodies to ifx (adas) at baseline * a contraindication to infliximab therapy * a contraindication to endoscopy * an ostomy * planned surgery * evidence of severe or unstable hepatic, gastrointestinal, cardiovascular, respiratory, neurological, psychiatric, hematological or renal disease at the discretion of the investigator, * pregnancy or breastfeeding, * treatment with any investigational drug in the past 30 days, or 5 half lives (whichever is longer).

Keywords: crohn's disease ulcerative colitis optimal use of infliximab
effects of walkbot-g robot-assisted gait training on anticipatory posture adjustment function and balance with cerebral palsy

Conditions: Cerebral Palsy; Spastic Hemiplegic Cerebral Palsy; Bilateral Spastic Cerebral Palsy; Gait Disorders, Neurologic

Summary: in children with cerebral palsy, the quality of walking decreases due to a decrease in the ability to control limbs, including walking, and coordination among various activities of daily living due to a decrease in functional independence and quality of life. gait disorder is one of the important therapeutic goals of children with cerebral palsy, and recently robot-assisted gait training (ragt) induces changes in brain plasticity, so it will help improve gross motor control and coordination control.


Eligibility criteria:
inclusion criteria: * patients aged 6-12 years or younger who have not received botulinum toxin or surgery within 3 months before the study * patients diagnosed with bilateral spastic cerebral palsy * patients diagnosed with spastic hemiplegic cerebral palsy exclusion criteria: * children who cannot understand and follow orders * children with stiffness in the lower limbs corresponding to the modified ashworth scale (mas)\> 3 * patients who wear a robot and walk without affecting contractures, deformities, or skin problems * infants with cardiovascular instability and mild scoliosis with a cobb's angle of 30 degrees or more
a systems-level intervention for rural adults with depression

Conditions: Depressive Symptoms

Summary: this study aims to test the effectiveness of a computer-assisted cognitive behavioral therapy for depression among rural adults. the intervention, called raising our spirits together (rost), was developed via a community-based participatory approach and will be delivered in small groups, facilitated by local pastors. groups will be held virtually, or in-person at two churches in rural michigan. eighty-four individuals will be recruited from hillsdale, michigan, to test the effect of rost on depressive symptoms, compared to an enhanced control condition (ecc).


Eligibility criteria:
inclusion criteria: * must live in hillsdale, lenawee, jackson, or calhoun county, michigan * positive screen for at least mild depressive symptoms based on the the patient health questionnaire-9 (phq-9\>=5) exclusion criteria: * non-english speaking * currently receiving cognitive behavioral therapy (cbt) for depression * ever completed a course of cognitive behavioral therapy (cbt; \>=8 sessions) * diagnosis of a psychotic disorder * current use of opiates or freebase cocaine * prominent suicidal/homicidal ideation with imminent risk.
assessment of compliance with antihypertensive telmisartan therapy

Conditions: Hypertension

Summary: the purpose of this study is to asses the efficacy and safety of telmisartan depending on the use of an electronic therapy monitoring device (helpinghand) in a real life setting and to asses patients compliance to the therapy with telmisartan in relation to use of electronic therapy monitoring device.


Eligibility criteria:
inclusion criteria: * age over 18 * untreated or ineffectively treated arterial hypertension exclusion criteria: * cholestatic disorders and severe hepatic failure * allergy to telmisartan * pregnancy and lactation period * unwillingness to participate in the study * inability to use the drug reminder device * unwillingness to use the drug reminder device
lavage of the uterine cavity for diagnosis of ovarian cancer

Conditions: High Grade Ovarian Serous Adenocarcinoma; Stage III Ovarian Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8

Summary: the goal of this project is to develop a minimally invasive test to detect ovarian cancer, by searching for mutations from the tumor in samples obtained from the cervix (pap smears), and from the uterus (uterine lavage) in participants with advanced ovarian cancer and in participants with increased risk of ovarian cancer due to inherited mutations, such as brca or brca2 (among others). pap smear and uterine lavage samples will be collected while the participant is under anesthesia for planned debulking surgery. a novel, highly sensitive and accurate technique, crispr-duplex sequencing, will be used to detect tumor associated mutations in tp53 (the most commonly mutated gene in ovarian cancer) within these samples. these results will be compared to sequencing results in the tumor itself for comparison, and pap and uterine lavage will be compared to each other to determine the optimal test. ultimately, the goal is to use the results of this study to plan a larger study including women without cancer who are at either increased risk or normal risk of ovarian cancer, for use in early detection.

outline: participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. dna is then extracted from the samples and sequenced for tp53 mutations using crispr-duplex sequencing.

Eligibility criteria:
inclusion criteria: * with suspected advanced ovarian cancer or genetic predisposition to malignant neoplasm of the ovary * planned surgery * have a uterus and no history of tubal occlusion exclusion criteria: * unable to speak english * unable to provide informed consent * prior hysterectomy
study of mgcd0103 given three times weekly in patients with relapsed and refractory lymphoma

Conditions: Lymphoma

Summary: in this study, mgcd0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.


Eligibility criteria:
inclusion criteria: * pathologic confirmation of relapsed or refractory lymphoma. 1. dlbcl stage ii-iv 2. follicular lymphoma * at least one site of measurable disease (≥ 2.0 cm with conventional techniques; physical exam \[pe\], ct, x-ray, mri). * prior treatment: 1. dlbcl cohort: disease progression following initial therapy and transplant (unless the patient is ineligible or refused transplant). there is no limit to number of prior therapies. 2. follicular lymphoma cohort: follicular lymphoma that is relapsed following or refractory to standard therapy and/or existing therapies or are not eligible for or are unlikely to achieve clinical benefit from those therapies. patients must have failed 3 or more prior therapies. * must have at least one of the following considered related to disease: 1. local symptoms due to progressive or bulky nodal disease. 2. compromise of normal organ function due to progressive or bulky disease. 3. presence of systemic b symptoms. 4. presence of symptomatic extranodal disease. 5. cytopenias due to extensive bone marrow infiltration, autoimmune hemolytic anemia or thrombocytopenia, or hypersplenism. * ecog performance status of 0 or 1. * aged 18 years or older. * laboratory requirements. exclusion criteria: * patients with another active cancer (excluding basal cell carcinoma or cervical intraepithelial neoplasia \[cin/cervical in situ\] or melanoma in situ). prior history of cancer is allowed, as long as there is no active disease. * pregnant or lactating women. * patients with uncontrolled intercurrent illness, active or uncontrolled infections, or a fever \>38.5 celsius (not due to tumor fever) on the day of scheduled dosing. * patients with a history of pericardial disease. * patients with small, moderate or large pericardial effusions or patients with a diagnosis of pericarditis. * patients with significant cardiac abnormalities. * patients with serious illnesses, medical conditions, or other medical history which would be likely to interfere with patient's participation in the study or with the interpretation of the results. * patients who have been treated with any investigational drug within 28 days prior to study initiation. * known hypersensitivity to hdac inhibitors and to any components of mgcd0103. * known human immunodeficiency virus (hiv) or active hepatitis b or c. * central nervous system lymphoma and lymphoma involving leptomeningeal area.

Keywords: relapsed and refractory lymphoma phase ii